Prospective ctDNA Monitoring in Exceptional Responders to Immunotherapy: A Pilot Study

Sponsor:

MUSC

Sponsor Study ID:

103387

CTO #:

103387

NCT Number:

NCT99999999

Phase:

N/A

Protocol Type:

Basic Science

Age Group:

Adults

Disease Sites:

Bladder; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Urinary; Prostate; Soft Tissue

Study Objectives:

Evaluate the association between ctDNA status (detectable vs non-detectable) at the time of progression and duration of exceptional response (DOER). Evaluate the association between ctDNA levels measured over time and DOER. Evaluate the association between rising vs not rising (stable or non-detectable) ctDNA levels and DOER. Characterize ctDNA levels in patients who resume immunotherapy in setting of progressive disease (PD). Estimate median overall survival (OS).

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)